Specifically targeting the AP in PNH and aHUS may be beneficial since it accounts for approximately 80% of the terminal pathway activity (90, 91) and may prevent both extravascular and intravascular hemolysis in PNH while preserving many of the functions of the CP and lectin pathway (LP). Here, CP is linked to paroxysmal nocturnal hemoglobinuria.